103 related articles for article (PubMed ID: 35491532)
1. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Miyamoto S; Heerspink HJL; de Zeeuw D; Toyoda M; Suzuki D; Hatanaka T; Nakamura T; Kamei S; Murao S; Hida K; Ando S; Akai H; Takahashi Y; Koya D; Kitada M; Sugano H; Nunoue T; Nakamura A; Sasaki M; Nakatou T; Fujimoto K; Kawanami D; Wada T; Miyatake N; Yoshida M; Shikata K;
Diabetes Obes Metab; 2022 Aug; 24(8):1429-1438. PubMed ID: 35491532
[TBL] [Abstract][Full Text] [Related]
2. Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial.
Greeviroj P; Puapatanakul P; Phannajit J; Takkavatakarn K; Kittanamongkolchai W; Boonchaya-Anant P; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Clin Nephrol; 2023 Nov; 100(5):224-230. PubMed ID: 37675488
[TBL] [Abstract][Full Text] [Related]
3. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL
Clin J Am Soc Nephrol; 2023 Jun; 18(6):748-758. PubMed ID: 36999981
[TBL] [Abstract][Full Text] [Related]
4. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
[TBL] [Abstract][Full Text] [Related]
6. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
[TBL] [Abstract][Full Text] [Related]
7. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
Doi Y; Hamano T; Yamaguchi S; Sakaguchi Y; Kaimori JY; Isaka Y
Diabetes Obes Metab; 2023 Oct; 25(10):2944-2953. PubMed ID: 37385955
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
Taylor SI; Cherng HR; Shahidzadeh Yazdi Z; Montasser ME; Whitlatch HB; Mitchell BD; Shuldiner AR; Streeten EA; Beitelshees AL
Diabetes Obes Metab; 2023 Dec; 25(12):3512-3520. PubMed ID: 37608471
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study.
Ishibashi T; Morita S; Furuta H; Nishi M; Matsuoka TA
Sci Rep; 2023 Sep; 13(1):16373. PubMed ID: 37773087
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
Nakhleh A; Abdul-Ghani M; Gazit S; Gross A; Livnat I; Greenbloom M; Yarden A; Khazim K; Shehadeh N; Melzer Cohen C
Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053
[TBL] [Abstract][Full Text] [Related]
11. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
Durkin M; Blais J
Diabetes Ther; 2021 Feb; 12(2):499-508. PubMed ID: 33340064
[TBL] [Abstract][Full Text] [Related]
12. Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!
Certo M; Niven J; Mauro C
Cell Chem Biol; 2023 Sep; 30(9):1009-1011. PubMed ID: 37738952
[TBL] [Abstract][Full Text] [Related]
13. Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial.
Hara A; Shimizu M; Hamaguchi E; Kakuda H; Ikeda K; Okumura T; Kitagawa K; Koshino Y; Kobayashi M; Takasawa K; Hisada Y; Toyama T; Iwata Y; Sakai N; Wada T
Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00159. PubMed ID: 32704573
[TBL] [Abstract][Full Text] [Related]
14. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Mohebi R; Liu Y; Hansen MK; Yavin Y; Sattar N; Pollock CA; Butler J; Jardine M; Masson S; Heerspink HJL; Januzzi JL
Cardiovasc Diabetol; 2023 Jul; 22(1):176. PubMed ID: 37438734
[TBL] [Abstract][Full Text] [Related]
15. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
16. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Namba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
Sci Rep; 2022 Sep; 12(1):15449. PubMed ID: 36104378
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter study of the efficacy and safety of cold forceps polypectomy for ≤ 6-mm non-ampullary duodenal low-grade adenomas.
Kanzaki H; Horii J; Takenaka R; Nakagawa H; Matsueda K; Tsuzuki T; Kita M; Yamasaki Y; Tanaka T; Iwamuro M; Kawano S; Kawahara Y; Tomoda J; Okada H
Endosc Int Open; 2022 Jun; 10(6):E712-E718. PubMed ID: 35859656
[No Abstract] [Full Text] [Related]
18. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K; Hida T; Nokihara H; Morise M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Yoshimoto T; Takata S; Tamura T
ESMO Open; 2022 Aug; 7(4):100527. PubMed ID: 35843080
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Hosokawa S; Ichihara E; Harada D; Kuyama S; Inoue K; Gemba K; Ichikawa H; Kato Y; Oda N; Oze I; Tamura T; Kozuki T; Umeno T; Kubo T; Hotta K; Bessho A; Maeda Y; Kiura K
Int J Clin Oncol; 2022 Jul; 27(7):1139-1144. PubMed ID: 35534642
[TBL] [Abstract][Full Text] [Related]
20. Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Kurozumi A; Hatazaki M; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Kato K; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2023 Jun; 22(1):143. PubMed ID: 37349722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
